The FDA has greatly limited who it says should be given the Alzheimer's drug Aduhelm
The FDA has greatly limited who it says should be given the Alzheimer's drug Aduhelm, which it approved last month for all patients despite the drug being designed for those dealing with mild symptoms.gettyA new label on the drug's packaging now recommends it only be given to early stage Alzheimer's patients.
On June 7, the FDA approved the drug for all patients, despite concerns over its effectiveness and cost. The drug comes with a price tag of $56,000 a year, which does not include costs for additional testing and scans patients would need. The expensive cost of Aduhelm combined with the fact around 6 million Americans suffering from Alzheimer’s disease would have been eligible—and unlikely to benefit from the drug—sparked concerns it would have caused an undue financial burden for Medicare.
Around 2 million Americans will still be eligible will be eligible under the revised drug labeling, according to“Biogen submitted a label update based on dialogue with FDA, physicians and patient advocates to further clarify the patient population,” Biogen spokeswoman Cindy Manieri said in a statement.An independent FDA advisory panel told the agency it should not approve the drug, but the FDA did so anyway.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Narrows Suggested Uses for New Alzheimer’s DrugThe agency recommended Aduhelm be prescribed only for patients in early stages of the disease, a move that could reduce the cost to the federal Medicare program.
Read more »
FDA recommends limits on use of Alzheimer's drug amid backlashA month after approving a controversial new Alzheimer’s drug, U.S. health regulators on Thursday signed off on new prescribing instructions that are likely to limit its use.
Read more »
FDA trims use of contentious Alzheimer's drug amid backlashU.S. health regulators on Thursday approved new prescribing instructions that are likely to limit use of a controversial new Alzheimer’s drug. The Food and Drug Administration said the change is intended to address confusion among physicians and patients about who should get the drug, which has faced an intense public backlash since its approval last month. The new drug label emphasizes that the drug, Aduhelm, is appropriate for patients with early or mild Alzheimer's but has not been studied in patients with more advanced disease.
Read more »
Pfizer to seek FDA authorization for 3rd COVID-19 vaccine doseResearch shows two doses of mRNA vaccines offer strong protection against the highly contagious delta variant.
Read more »
Calls mount on FDA to formally endorse Covid vaccines as Delta surgesSome medical experts have been calling on regulators to endorse what they say the data already shows — that the Pfizer and Moderna vaccines safely and effectively prevent severe illness, hospitalization and death from the coronavirus
Read more »